| 摘要 |
A method of predicting a likelihood of a clinical outcome for a patient with prostate cancer, comprises (a) determining levels of RNA transcripts of the following genes: BGN, COL1A1, COL3A1, SFRP4, FLNC, GSN, TPM2, GSTM2, FAM13C, KLK2, AZGP1, SRD5A2, and TPX2 in a biological sample containing cancer cells obtained from the patient; (b) normalizing the level of the RNA transcripts to obtain normalized gene expression levels; (c) calculating a quantitative score (QS) for the patient. The quantitative score (QS) is calculated as follows: QS = 0.735 x ECM (Stromal Response) group score -0.368 x Migration (Cellular Organization) group score -0.352 x PSA (Androgen) group score + 0.095 x Proliferation (TPX2) score where ECM (Stromal Response) group score = 0.527 x BGN + 0.457 x COL1A1 + 0.156 x SFRP4 Migration (Cellular Organization) group score = 0.163 x FLNC + 0.504 x GSN + 0.421 x TPM2 + 0.394 x GSTM2 PSA (Androgen) group score = 0.634 x FAM13C + 1.079 x KLK2 + 0.642 x AZGP1 + 0.997 x SRD5A2 Threshold score Proliferation (TPX2) score = TPX2 Threshold score and where SRD5A2 Threshold Score = { 5.5 if SRD5A2 < 5.5 and SFD5A2 otherwise} , and TPX Threshold score = { 5.0 if TPX2 < 5.0 and TPX2 otherwise} and where the gene symbols in the equations represent the normalized gene expression levels of the RNA transcripts of the respective genes. The method further comprises (d) predicting a likelihood of a clinical outcome for the patient based on the quantitative score. |
